{"name":"Dong-A Pharmaceutical","slug":"dong-a-pharmaceutical","ticker":"","exchange":"","domain":"donga.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"DA-8159 (Udenafil)","genericName":"DA-8159 (Udenafil)","slug":"da-8159-udenafil","indication":"Erectile dysfunction","status":"phase_3"},{"name":"G-0081","genericName":"G-0081","slug":"g-0081","indication":"Other","status":"phase_1"},{"name":"DA-5515","genericName":"DA-5515","slug":"da-5515","indication":"Other","status":"marketed"},{"name":"Exforge®","genericName":"Exforge®","slug":"exforge","indication":"Other","status":"marketed"},{"name":"G3041","genericName":"G3041","slug":"g3041","indication":"Other","status":"phase_1"},{"name":"Placebo of DA-5515","genericName":"Placebo of DA-5515","slug":"placebo-of-da-5515","indication":"Clinical trial control arm (not a therapeutic indication)","status":"marketed"},{"name":"SI000413","genericName":"SI000413","slug":"si000413","indication":"Other","status":"phase_2"},{"name":"SR-exenatide","genericName":"SR-exenatide","slug":"sr-exenatide","indication":"Other","status":"phase_1"},{"name":"r-hCG","genericName":"r-hCG","slug":"r-hcg","indication":"Induction of ovulation and pregnancy in infertile women who do not ovulate","status":"phase_3"}]}],"pipeline":[{"name":"DA-8159 (Udenafil)","genericName":"DA-8159 (Udenafil)","slug":"da-8159-udenafil","phase":"phase_3","mechanism":"DA-8159 (Udenafil) inhibits phosphodiesterase type 5 (PDE5), increasing cyclic GMP levels to promote smooth muscle relaxation and improve blood flow.","indications":["Erectile dysfunction"],"catalyst":""},{"name":"G-0081","genericName":"G-0081","slug":"g-0081","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DA-5515","genericName":"DA-5515","slug":"da-5515","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Exforge®","genericName":"Exforge®","slug":"exforge","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"G3041","genericName":"G3041","slug":"g3041","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo of DA-5515","genericName":"Placebo of DA-5515","slug":"placebo-of-da-5515","phase":"marketed","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","indications":["Clinical trial control arm (not a therapeutic indication)"],"catalyst":""},{"name":"SI000413","genericName":"SI000413","slug":"si000413","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SR-exenatide","genericName":"SR-exenatide","slug":"sr-exenatide","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"r-hCG","genericName":"r-hCG","slug":"r-hcg","phase":"phase_3","mechanism":"r-hCG is a recombinant human chorionic gonadotropin used to stimulate ovulation and treat infertility.","indications":["Induction of ovulation and pregnancy in infertile women who do not ovulate"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQWkpvT1pGOEZIN0RGUzBYSnIySUVXZ1ZwSktrM3RIZVRTMTJzMHB4QnhSb3JKUTBaTDhTS2lNRWdrLVBJY0lWVG84NzVKZHBSWUZER0NKWVhpbnlucjJxMzVDbnc0ZGRUbmk0VHM3aEZOZ1RzSDZLaUItZEZBb0V4ddIBlAFBVV95cUxQb0lDODZPemhRVkhZWHd2bXBMSVZQYXp6Ukx0TXAxTGZCb2Zmb3VoOExEbjdzYlRsUTQzT3VTT3BpQWNRMWVEeXZUWTJ1MG1fUlBBczFWVFdIQ3N0ZlpvLS1vQXdPUFo4dnUwSDlGRTVSR2FNa3RsdjFSUWl6eldFbUZNRGxVRzV3c1U1Qk9wVjN0RVBU?oc=5","date":"2026-04-06","type":"pipeline","source":"Chosunbiz","summary":"Korea pharma shifts to external hires as price cuts push global R&D - CHOSUNBIZ - Chosunbiz","headline":"Korea pharma shifts to external hires as price cuts push global R&D - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNUTZoaUFRRW5XbzB0WWNWNi0zcDVieHNhWHlRQ3lmZTVJa21LTXBiWDJMN29xekRSX2RfamVDTXVRMUNYLUIzczJvNjRJc2piajhvcFFuaHJoTkYxYnRHTUhpdy1VMGRYZ3NrTk9USmlrdnlGc3laS2RvQXhYNTJWeEdmYllnWUo4aTFyQUtURERGZWlLMjVzRENkOA?oc=5","date":"2026-03-19","type":"pipeline","source":"Seoul Economic Daily","summary":"Dong-A Socio Holdings Posts Record Results on Pharma-Bio-Logistics Triad - Seoul Economic Daily","headline":"Dong-A Socio Holdings Posts Record Results on Pharma-Bio-Logistics Triad","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE83UWRhdXZITVc5RWJINkVfU0dPU3pGeGxBTkxqU1o2WHpJT1JnNDlyeFUzX0tqYThSdEhLMTVZaENvRnR5ZzlWRU16N0JIalpGUFpuRVBxX192UUZpb3JCcjZPOERtb3BKcmc3MFlR0gFyQVVfeXFMUHJFMjFOWXFiUlZWWVlpWlM1THJoWmgxUDNEdE01cG8xN3lkaDRtYVI4TEJnNV9xYWZXT3Q4NnVGbk5pX01scWRkUnJOeVRROGdwZmdXT01sZk1kZ0t5UHJpVGlkSV9hS01vb0RWbU41emJR?oc=5","date":"2026-02-10","type":"earnings","source":"koreabiomed.com","summary":"Dong-A ST achieves record annual revenue fueled by prescription drug and overseas growth - koreabiomed.com","headline":"Dong-A ST achieves record annual revenue fueled by prescription drug and overseas growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQNnI1eEx0akVzc25uZzFrMDBqWWlDYWRyYWZHWjBsdjc5eWFMeFVYUkpBZVN0T2ViOXlCQnBnc0gzLXNGQzJiWmlSVTlhYlV4dm43SW80QW1WVmVWWm1PTzNldklhTkxDc1JPYlhyWlBRN0RYWXQ4M01jN1IwSkdHTHFoV2pKY0l6V3JsRDBNekxpZWdfMGVSWVlWZE04eTJpX0dXVkppZEswMU5DdHRxaHF3M25uYzNIdVowTDU4cTVqUkxTQ2FTUmY1V05Bc0k?oc=5","date":"2026-01-20","type":"pipeline","source":"NutraIngredients.com","summary":"Dong-A launches first liquid sleep aid, pharmacy-exclusive health functional foods - NutraIngredients.com","headline":"Dong-A launches first liquid sleep aid, pharmacy-exclusive health functional foods","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE44RkZadWZnYmwwVVRRUXA5cFkyUU1DNUhtaW1xcVgxSmllc2VKbk4xQk16cDJVQ3dOeW9kZDY3TnZFRkxfMzROTE9KajJBTzRTdTJ2QVExamVFUQ?oc=5","date":"2025-08-28","type":"pipeline","source":"theinvestor.co.kr","summary":"Donga Pharm launches wound treatment for children - theinvestor.co.kr","headline":"Donga Pharm launches wound treatment for children","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5oQ0pfX2dNLUNtQWhCWlpRYUdpQmUxWnAtQ2F2UnRpSWU1SEMzSzBPYUpUWVpaYXdjYTRzZ2dSM0hJN3U0Tk1hc3BZTHZ0N01YWFlnTF9DbnhfemI0cHdsRHBZWnRnOENLZjg1RkxB0gFyQVVfeXFMT0lVejhsTHlmWm9rZ3dQb1NTUkY2QUFMc2JnZTdGYjkxWVJLbDJkd3EwUkRXN1Q3NzVzaVhBQ1J5SF8ybm4yY1JyN24wb2pWY2JoVmtVNkI4RkhTY0xnZG9RQjJxcGNrZXVadlVJSnV3ajd3?oc=5","date":"2025-08-26","type":"pipeline","source":"koreabiomed.com","summary":"Dong-A ST speeds up developing new drugs utilizing AI - koreabiomed.com","headline":"Dong-A ST speeds up developing new drugs utilizing AI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBKOHRFZmp5bXFoRnZtdTJkbGwwaTVMNnp6RnBtYzV2SFBETW8xQ3d2eXZldTg4R2puaGxlRU9hc1lqYVVrdlg4TGJ2cnJtMlJoMktkUVFsNGplNFhySGNR?oc=5","date":"2025-08-19","type":"patent","source":"동아비즈니스리뷰 | DBR","summary":"Dong-A ST Launches Stelara Biosimilar in U.S. - 동아비즈니스리뷰 | DBR","headline":"Dong-A ST Launches Stelara Biosimilar in U.S. - 동아비즈니스리뷰 | DBR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBHWnZGOVpEbjQyZlpnVlBvQWtyUkdXNHBWTWFXSDFLQlVYbTNuSDRMVTNJSGdzMHU1Z0hPOFdEbmR3ZUNLZXJ5SV9rZ29tak40d1dBcGR4SWdWVmtMX0xrbVJJZm52akp5NDNvTzdR0gFyQVVfeXFMTkJFQm15NnBENEFHdnBsVjBsTHdSUDlzTEk2eG9Id0NSSXF6NTRSbFNiM2VHOUF4QWc2VERjNjQwSDFyWGFERTZJRm9INVVaUTBDbWw0Y2dCWWRQWnpmNnQ1My1fMW5FdUl4MndHdGFxS2hn?oc=5","date":"2025-06-23","type":"pipeline","source":"koreabiomed.com","summary":"Dong-A ST, Hanmi Pharm showcase obesity, MASH drug candidates at ADA 2025 - koreabiomed.com","headline":"Dong-A ST, Hanmi Pharm showcase obesity, MASH drug candidates at ADA 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE0zdldKa1poZ2ZaM3RZREJhN3FkbjItVXJFRzV4UHN1enNPQXE1aWNtYUNmaEtfd1RfRXN5WlZXOEZ4ZGhYMDdwWkltUkY5T2x6T2dycWM3WkVqaXk2WUZldFNucG02TnMyOVZkUFpB0gFyQVVfeXFMT0xiWDNjSmZxODlvREgwb1BjWGhMNVN2OW1qbFMwTGM3azRrUVRmSmlYbHNCT0pGdHFjN213LWtpQmZXUG9feTByN1FkWWlzZmRCaHU0MlZXZ25zRXhxdU5meWRnZ0g3cDV0eGlxQ2hRVkZ3?oc=5","date":"2025-02-06","type":"pipeline","source":"koreabiomed.com","summary":"Dong-A Pharm's skincare brand Fation enters Malaysia and Singapore - koreabiomed.com","headline":"Dong-A Pharm's skincare brand Fation enters Malaysia and Singapore","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxONVg3eUJKbHRPdDh4QkpUQzFfbHNsdUFwelZ6SW1CelVVdnQ0emczU0w4LUUwRVlaTUFvcmJxdGZ6NFgtank5bnFhaUlhVnRSRG5iSnVXYmxJMWhrcWNYTjM4Q2M1MUFYaFRRNndjeHByZ2tPUHlmM3RWQk9TcW51bUtkam84RjFEbnJyT1I3ZzRkb3EtZlBlT3RFRU5IdDRJU2I2QTUxVDNmdzVUS3Zsdk1VVUNTZw?oc=5","date":"2024-10-29","type":"pipeline","source":"NutraIngredients.com","summary":"South Korea’s Dong-A Pharma targets SEA markets with kids, beauty supplement range - NutraIngredients.com","headline":"South Korea’s Dong-A Pharma targets SEA markets with kids, beauty supplement range","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPV3dIN2F0dDdTb3ljZTNSMnFoZ0VDNGgzbFJrSU1LRVgzZmx1dVFZcFFLbUIxaTJHVjJwa2FualVLVEdUbjI1Zm5fRFdQXzZMNS00eGNBTDV0ZGplTlhZdUJTZUllZDBPSEVHaEZyZFVpQzNITnRqcE51RmI0cG51eTBIY2txMlZYZ1F5NVZXcURIX19leEZzM3VDMWtPTVA4eVpHRVdJS3hYNkU1LXpqS3RJUm0tWE5xMm5XTzl2ajZ4OG9iUjBkUU5SeDZyUQ?oc=5","date":"2024-10-11","type":"regulatory","source":"businesswire.com","summary":"US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® - businesswire.com","headline":"US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFAyMl8zNkRsekdhcW9tM3g0Wk9XSjRxVlIyVThaMHlrTHVvQVpfZEJsSGNNRXB1UXFJTEVOS3oyXzZDeHFocUtDc3FNd09abzdQWTh0V3J5RVhiQjVpUEJVMHB2QnB2UXlmSC1RbHRn?oc=5","date":"2022-12-23","type":"pipeline","source":"KED Global","summary":"Dong-A ST incorporates NeuroBo as subsidiary - KED Global","headline":"Dong-A ST incorporates NeuroBo as subsidiary","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_3":2,"phase_1":3,"marketed":3,"phase_2":1},"enrichmentLevel":0,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}